Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Sucampo Pharmaceuticals, Inc.exh_322.htm
EX-32.1 - EXHIBIT 32.1 - Sucampo Pharmaceuticals, Inc.exh_321.htm
EX-31.2 - EXHIBIT 31.2 - Sucampo Pharmaceuticals, Inc.exh_312.htm
EX-31.1 - EXHIBIT 31.1 - Sucampo Pharmaceuticals, Inc.exh_311.htm
EX-10.1 - EXHIBIT 10.1 - Sucampo Pharmaceuticals, Inc.exh_101.htm
EX-2.1 - EXHIBIT 2.1 - Sucampo Pharmaceuticals, Inc.exh_21.htm
10-Q - FORM 10-Q - Sucampo Pharmaceuticals, Inc.f10q_050317p.htm

Exhibit 12.1

 

   Ratio of Earnings to Fixed Charges
   Year to date
March 31,
  Year ended December 31,
(in thousands, except for ratio)  2017  2016  2015  2014  2013  2012
                   
Pretax income from continuing operations  $8,209   $14,375   $43,675   $27,133   $10,943   $7,977 
                               
Fixed charges:                              
Interest expense   2,890    23,761    6,854    1,520    1,894    2,346 
                               
Earnings (a)   11,099    38,136    50,529    28,653    12,837    10,323 
                               
Fixed charges (b)   2,890    23,761    6,854    1,520    1,894    2,346 
                               
Ratio of earnings to fixed charges (a/b)   3.8    1.6    7.4    18.9    6.8    4.4